BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
SUBSCRIBE
BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
BullScope
No Result
View All Result
Home Bargains & Bubbles

Microsoft Is Earning More Than Ever. The Stock Is Priced Like a Doubt Has Set In.

Moe Alsumidaie by Moe Alsumidaie
November 20, 2026
in Bargains & Bubbles
0
74
SHARES
1.2k
VIEWS
Share on XShare on LinkedInShare on Facebook

The gist of it

Microsoft’s most recent quarterly filing shows net income growing 32% year-over-year, and net margins that just crossed 40% for the full fiscal year, the highest in the company’s modern history. The stock, at $498, sits at a price-to-earnings ratio that our data places in the 13th percentile of its own decade, meaning the market is paying less of a premium for each dollar of Microsoft’s profit than it has in roughly nine of the last ten years. The math says the business is accelerating. The mood says something is making investors hesitant. Those two readings cannot both be right, and that disagreement is the story.

A company that used to sell software boxes now runs the world’s AI plumbing

Microsoft spent most of the 2000s selling Windows licenses and Office discs, a good business that grew slowly and attracted a modest valuation. Then, over roughly a decade, it rebuilt itself around cloud computing, the practice of renting computing power and software over the internet rather than selling a product once. That shift compounded quietly until the arrival of ChatGPT in late 2022 turned “AI infrastructure” from a buzzword into a capital-spending emergency for every large company on earth. Microsoft, already deeply embedded in corporate technology through its Azure cloud platform and its early bet on OpenAI, found itself holding the pipes everyone suddenly needed.

The result shows up cleanly in the filed numbers. Full fiscal year 2026 revenue reached $331.8 billion, up 18% from the year before, and net margin, the share of each dollar of sales left over after every bill is paid, hit 40.3%. That margin figure matters because it is the highest in the data set our engine tracks, and it arrived in a year when the company was simultaneously pouring money into new data centers. Growing faster while keeping more of each dollar is not the normal direction of travel for a company spending at this scale.

The quarter that changes the frame

The most recent quarter sharpens the picture further. For the three months ended September 30, 2026, Microsoft reported $92.3 billion in revenue, a 19% increase year-over-year, and net income up 32%. To put that in graspable terms: the company earned more in net profit in a single quarter than most S&P 500 companies earn in an entire year of revenue.

BullScope TerminalMicrosoft was the article. The engine is the product.Same yardsticks, any ticker: filed financials in, math-vs-mood out. Nothing here is advice; it is the evidence, organized.Run another company →

Azure, the cloud platform that now sits at the center of Microsoft’s AI story, grew 48% in the quarter. For context, Azure’s quarterly revenue alone is now larger than the full annual revenue of most Fortune 500 companies. Management guided for continued acceleration in the current quarter, in constant currency, meaning after stripping out the effect of exchange-rate swings.

For a saver trying to understand why any of this matters: when a cloud platform grows this fast, it means businesses are signing long-term contracts to run their software and AI workloads on Microsoft’s servers rather than building their own. Those contracts, which analyst consensus data aggregated by Stock Analysis (linked in sources) puts at $677 billion in total commercial backlog, are revenue that is already committed. The pipeline is visible in a way that most businesses cannot claim.

The bill for all of it

Here is where the mood’s hesitation finds its footing. Free cash flow, which is the cash a business actually generates after paying for the equipment and buildings it needs to keep running, fell 27% in the quarter despite record profits. The reason is capital expenditure: Microsoft spent roughly double what it spent a year ago on property and equipment in a single quarter. The company has also signed datacenter leases not yet started that total hundreds of billions of dollars, a commitment larger than the entire annual revenue of most countries.

Think of it this way at kitchen-table scale. A family earns $100,000 a year and clears $40,000 after expenses, a record margin. But they also just signed contracts to build a new workshop costing several times their annual income over the coming years, with a large chunk already spent this quarter alone. The income statement looks extraordinary. The checkbook tells a different story about what comes next.

Microsoft’s own filings acknowledge the risk plainly: the 10-Q notes that heavy reliance on short-lived GPU and CPU assets, roughly three-quarters of the capital spending goes to chips rather than long-lived buildings, could compress margins if AI usage does not keep pace with capacity. The company brought two dozen new data centers online in the quarter, and management projects capital expenditures will climb further through the full fiscal year.

BullScope TerminalWant the full evidence sheet behind pieces like this?The terminal runs the complete workup: Microsoft and 500+ other names, on the same official data.See the evidence engine →

What the price is paying for

The stock trades at a price-to-earnings ratio, the price tag per dollar of annual profit, of 28.1, according to our data. The median P/E for Microsoft over the past decade is 34.7. That means today’s buyer is paying less per dollar of earnings than the market has typically demanded, placing the current valuation in the 13th percentile of its own history.

The math here is the filed fundamentals: accelerating revenue growth, expanding margins, and a cloud backlog that makes future revenue unusually visible. The mood is what the market is currently willing to pay for those fundamentals, and right now it is paying less than it has in nine of the last ten years. The gap between those two readings is not small.

As of mid-November 2026, third-party aggregators (BeInsure and MarketBeat, linked in sources) report that a number of sell-side analysts have filed price objectives above the current price and carry positive ratings on the security, with their stated rationale centering on Azure growth and backlog visibility. BullScope does not adopt, endorse, or reproduce those figures as analytical conclusions; they are cited solely to illustrate how external analysts are characterizing the gap between filed fundamentals and current price. The bear case, implicit in the current price, is that the capital spending does not earn an adequate return, and that margins will compress before the AI infrastructure pays off.

The data cannot yet resolve that question. What it can say is that the business, measured by what it files, is performing at the high end of its own history, and the price, measured against that same history, is not.

Reading the numbers

Net margin, 40.3% (FY2026). A net margin is what a company keeps from each dollar of sales after paying every cost, tax, and interest charge. For every dollar Microsoft billed in fiscal 2026, it kept just over forty cents as profit. A typical large software company keeps twenty to twenty-five cents. A household earning $80,000 and keeping $32,000 after all expenses would be operating at this margin, which is exceptional by any measure.

BullScope TerminalYou just read Microsoft’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →

Azure revenue growth, 48% (Q1 FY2027). This is how much faster Azure’s revenue grew compared to the same quarter a year earlier. If a landlord collected $100 in rent last October and $148 this October, that is 48% growth. Sustained at anything near this rate, Azure’s contribution to total revenue doubles in under two years.

Free cash flow, $18.6 billion (Q1 FY2027, down 27% year-over-year). Free cash flow is what remains after a company pays for the physical assets it needs to operate, the cash available to pay dividends, buy back shares, or reduce debt. Microsoft earned record profits but generated less free cash than a year ago because it spent $39.4 billion on chips and data centers in a single quarter, more than double the prior year. A business earning well but reinvesting aggressively is not the same as a business in distress, but the distinction matters for anyone trying to understand what the company’s cash position actually looks like.

P/E ratio, 28.1 versus decade median of 34.7 (our data). The P/E ratio is the price a buyer pays for each dollar of annual earnings. At 28.1, Microsoft’s current price tag per dollar of profit sits in the bottom 13% of its own decade-long range. IF the P/E ratio were to revert to its decade median of 34.7 and IF trailing earnings held near their current filed level, the arithmetic would place the price in the range of roughly $610 to $620, a mechanical illustration of the valuation gap, not a forecast of either condition occurring.

For the standing yardsticks on Microsoft: the price tag, the filed record, and the four gauges, refreshed with each edition, see the BullScope Evidence Sheet: Microsoft.

Sources

  • Microsoft 10-Q, quarter ended September 30, 2026 (SEC EDGAR)
  • Microsoft 10-K, fiscal year ended June 30, 2026 (SEC EDGAR)
  • Microsoft Q1 FY2027 earnings press release and webcast
  • Vested Finance: Microsoft Q1 FY27 results, Azure 48% growth
  • Plicit AI: Microsoft FY2027 Q1 balance sheet
  • Stock Analysis: Microsoft analyst forecasts and consensus
  • BeInsure: Microsoft analyst price targets, November 2026
  • MarketBeat: TD Cowen analyst rating reiteration, November 18, 2026
BullScope publishes impersonal research for a general audience. Nothing here is personalized investment advice, and nothing here is a recommendation to buy or sell any security. As of publication, neither BullScope nor its operator holds a position in any security, covered or otherwise; we do not trade at all, and we accept no compensation from any company we cover. When a conflict of interest exists, we do not publish: companies that compensate our operator in any capacity, or about which our operator could hold nonpublic information, are barred from coverage automatically, as described in the conflicts policy in our methodology. Figures come from company filings and public data through our published methodology; forecasts are conditional scenarios, not predictions and not promises. Markets carry risk, including loss of principal. Consider your own situation, or consult a licensed adviser, before acting on anything you read.
BullScope TerminalYou just read Microsoft’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →
Moe Alsumidaie

Moe Alsumidaie

Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.

Recommended For You

Vertex Pharmaceuticals: The Business Keeps Growing. The Price Already Knows.

by Moe Alsumidaie
November 16, 2026
0

Goldman Sachs sees a stock worth $725. A Seeking Alpha contributor, writing the same week, called it a sell. Both are looking at the same filed numbers. That...

Read moreDetails

Zoetis: The Business Keeps Earning. The Price Keeps Falling. The Gap Between the Two Is Unusually Wide.

by Moe Alsumidaie
November 10, 2026
0

For most of its decade as a public company, Zoetis traded like a luxury good, priced as if its grip on the animal-health market was permanent and its...

Read moreDetails

Biogen’s Crossroads: Five Years of Shrinking Revenue, a Stock Near Its All-Time High

by Moe Alsumidaie
November 2, 2026
0

Revenue has fallen every year since 2020. The stock just touched its 52-week high. Those two facts should not coexist, and the gap between them is the whole...

Read moreDetails

Amgen: The Stock Is Priced for a Future the Patent Cliff Might Not Allow

by Moe Alsumidaie
October 26, 2026
0

Amgen spent most of the 2010s as the quiet giant of biotech, printing cash from a handful of blockbuster drugs and returning nearly all of it to shareholders....

Read moreDetails

Abbott’s Split Personality: Revenue Climbs 14%, the Stock Falls Anyway

by Moe Alsumidaie
October 22, 2026
0

Abbott Laboratories spent most of the pandemic era as a Wall Street darling, its COVID test sales turning a steady healthcare conglomerate into a growth story. Then the...

Read moreDetails
Next Post

LifeVantage: A $58 Million Buyback Program and a Quarter That Lost Money

Please login to join discussion
BullScope
The Research Terminal
Run any stock through the BullScope evidence engine. Filings in, evidence out. Every number explains itself.
Open the Terminal
A BullScope product

Related News

Evidence Sheet: Visa (V)

November 6, 2026

Halozyme: The Royalty Machine Trading at a Premium to Its Own History

September 9, 2026

Evidence Sheet: Microsoft (MSFT)

October 29, 2026
BullScope

BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.

Prefer BullScope.ai on Google

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

No Result
View All Result
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

Not enough quota to unlock this post
Unlock left : 0
Are you sure want to cancel subscription?
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.